FineHeart S A: FineHeart Obtains Czech Health Authority Approval to Commence First in Human Clinical Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
€6 million of further funds raised in addition to the €15 million in June Clinical trials expected in 2022 FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER
The First In Human implantation of the ICOMS FLOWMAKER is assured following this financing FineHeart S.A, a preclinical medical device company that has developed theICOMS FLOWMAKER, an Implantable
FineHeart S.A: FineHeart Breaks New Ground With Successful Removal of the ICOMS FLOWMAKER in a 90-day In-vivo Trial
Easy removal with a beating heart without damage to the myocardium 30 days after implantation
Normal heart functioning 60 days after explantation
Completely sealed operation with dedicated implant fixation system
Quick recovery and short hospital stay
Autonomy and free from complications or infection, or structural damage to the heart and vital organs
FineHeart S.A a preclinical medical device company that has developed the
ICOMS FLOWMAKER, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the successful, simple, and breakthrough implantation and removal of its device in a 90-day in-vivo trial.
Wireless Transcutaneous Energy Transfer (TET) System for Powering a LVAD is Successful
FineHeart tests powers ICOMS Heart Pump and is a major step prior to first in human trials
The FineHeart Transcutaneous Energy Transfer (TET) System for the ICOMS cardiac assist device. 1. The ICOMS heart pump. 2. The implanted TET transfer pad. 3. The external energy transfer pad.
January 13, 2021 FineHeart, a preclinical-stage medical device company developing a novel left ventricular assist device (LVAD), successfully completed a seven-day study of its Transcutaneous Energy Transfer (TET) System for recharging the ICOMS implantable battery without any cords or drivelines through the skin.
FineHeart s TET is a system with no percutaneous driveline that transfers energy through the skin to charge the ICOMS pump battery. TET is rapidly implantable (less than 15 mins) and will give patients autonomy without the need for tethering cables from the device leading outside of the body. The elim